Synapse February 2013 focuses on injunctions against pharma patent infringement

In Synapse February 2013, Taylor Wessing discusses the issue of interim injunctions against pharmaceutical patent infringement. Synapse focuses on law for the life sciences industry.

The patent system gives innovators a monopoly right — a right that in the life science and pharmaceutical sector can be extremely valuable. It is perhaps unsurprising therefore that a manufacturer will go to some lengths to enforce their patent rights protecting a product.

A powerful tool for this purpose is the injunction, which — if deployed correctly — can stop a potential infringer in their tracks.

Other topics covered in Synapse February 2013 include: the Transparency Directive and the customs regulation.

To read more click here.